Hepatitis Monthly

Published by: Kowsar

A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy: A Meta-Analysis of Studies From 2008 to 2014

Ya Wen 1 , Yi Xiang Zheng 1 and De Ming Tan 1 , *
Authors Information
1 Viral Hepatitis Key Laboratary, Department of Infectious Disease, Xiangya Hospital, Central South University; Changsha, China
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e27181
  • Published Online: May 23, 2015
  • Article Type: Review Article
  • Received: January 20, 2015
  • Revised: March 1, 2015
  • Accepted: March 21, 2015
  • DOI: 10.5812/hepatmon.15(5)2015.27181

To Cite: Wen Y, Zheng Y X, Tan D M. A Comprehensive Long-Term Prognosis of Chronic Hepatitis C Patients With Antiviral Therapy: A Meta-Analysis of Studies From 2008 to 2014, Hepat Mon. 2015 ; 15(5):e27181. doi: 10.5812/hepatmon.15(5)2015.27181.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
References
  • 1. A new direction for hepatitis C. Lancet. 2014; 383(9925): 1270[DOI][PubMed]
  • 2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[PubMed]
  • 3. Lavanchy D. The global burden of hepatitis C. . Liver international : official journal of the International Association for the Study of the Liver. 2009; 29: 74-81
  • 4. Farci P. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome [Science 1989;244:359-362]. J Hepatol. 2002; 36(5): 582-5[PubMed]
  • 5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13): 975-82[DOI][PubMed]
  • 6. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286): 958-65[PubMed]
  • 7. Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon alpha-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. Iran Red Crescent Med J. 2012; 14(8): 466-9[PubMed]
  • 8. Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP. Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection. Hepat Mon. 2014; 14(11)[DOI][PubMed]
  • 9. Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, et al. The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon. 2014; 14(8)[DOI][PubMed]
  • 10. Sargolzaee Aval F, Behnaz N, Raoufy MR, Alavian SM. Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network. Hepat Mon. 2014; 14(6)[DOI][PubMed]
  • 11. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009; 49(3): 729-38[DOI][PubMed]
  • 12. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008; 135(3): 821-9[DOI][PubMed]
  • 13. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359(23): 2429-41[DOI][PubMed]
  • 14. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15): 2008-12[PubMed]
  • 15. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010; 52(5): 652-7[DOI][PubMed]
  • 16. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012; 27(2): 291-9[PubMed]
  • 17. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011; 9(6): 509-516 e1[DOI][PubMed]
  • 18. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A. Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Clin Gastroenterol Hepatol. 2011; 9(3): 249-53[DOI][PubMed]
  • 19. Alfaleh FZ, Alswat K, Helmy A, Al-hamoudi W, El-sharkawy M, Omar M, et al. The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int. 2013; 33(6): 871-83[DOI][PubMed]
  • 20. Di Martino V, Crouzet J, Hillon P, Thevenot T, Minello A, Monnet E. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat. 2011; 18(7): 493-505[PubMed]
  • 21. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010; 52(3): 833-44[DOI][PubMed]
  • 22. Yamasaki K, Tomohiro M, Nagao Y, Sata M, Shimoda T, Hirase K, et al. Effects and outcomes of interferon treatment in Japanese hepatitis C patients. BMC Gastroenterol. 2012; 12: 139[PubMed]
  • 23. Wang CH, Chang KK, Lin RC, Kuo JJ. Insights into hepatocellular carcinoma occurrence and long-term outcomes in patients with chronic hepatitis C infection after successful antiviral treatment. Hepatol Int. 2013; 7
  • 24. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol. 2013; 19(18): 2793-8[DOI][PubMed]
  • 25. Chang KC, Hung CH, Lu SN, Wang JH, Lee CM, Chen CH, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012; 67(11): 2766-72[DOI][PubMed]
  • 26. Ferreira Sda C, Carneiro Mde V, Souza FF, Teixeira AC, Villanova MG, Figueiredo JF, et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. Braz J Infect Dis. 2010; 14(4): 330-4[PubMed]
  • 27. Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol. 2013; 25(7): 798-805[DOI][PubMed]
  • 28. Trapero-Marugan M, Mendoza J, Chaparro M, Gonzalez-Moreno L, Moreno-Monteagudo JA, Borque MJ, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol. 2011; 17(4): 493-8[DOI][PubMed]
  • 29. Qu LS, Chen H, Kuai XL, Xu ZF, Jin F, Zhou GX. Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis: A meta-analysis of randomized controlled trials. Hepatol Res. 2012; 42(8): 782-9[PubMed]
  • 30. Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006; 13(6): 409-14[PubMed]
  • 31. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158(5 Pt 1): 329-37[PubMed]
  • 32. Behzadi MA, Ziyaeyan M. Hepatitis C Virus Load in Seropositive Liver and Kidney Transplant Recipients by Quantitative Real-Time PCR Before and After Transplantation. Jundishapur J Microbiol. 2013; 6(8)[DOI]
  • 33. Karimi Elizee P, Alavian SM, Miri SM, Behnava B, Alavian SH, Keshvari M, et al. The Seroprevalence of Entrically Transmitted Viral Hepatitis in HCV Infected Thalassemia and Hemophilia Patients in Iran. Jundishapur J Microbiol. 2013; 6(7)[DOI]
  • 34. Cakmakci E, Caliskan KC, Tabakci ON, Tahtabasi M, Karpat Z. Percutaneous liver biopsies guided with ultrasonography: a case series. Iran J Radiol. 2013; 10(3): 182-4[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments